Related Experiment Videos
A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG
C M Verity1, G Hosking, D J Easter
1Child Development Centre, Addenbrooke's Hospital, Cambridge.
Insights
Sodium valproate and carbamazepine show equal long-term efficacy for controlling childhood epilepsy. Both antiepileptic drugs had mild adverse events, with specific side effects noted for each medication.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Epileptology
Background:
- Epilepsy is a common neurological disorder in children.
- Primary generalized and partial epilepsy are prevalent types requiring effective treatment.
- Sodium valproate and carbamazepine are frequently prescribed antiepileptic drugs.
Purpose of the Study:
- To compare the long-term efficacy of sodium valproate versus carbamazepine in children with newly diagnosed epilepsy.
- To evaluate and compare the adverse-event profiles of these two antiepileptic drugs over a three-year period.
Main Methods:
- A randomized, controlled trial involving 260 children with newly diagnosed epilepsy.
- Participants were assigned to receive either oral sodium valproate (N=130) or oral carbamazepine (N=130).
- Children were followed for three years, with dosage adjustments based on seizure control and toxicity.
Main Results:
- Both sodium valproate and carbamazepine demonstrated comparable efficacy in achieving high seizure control levels.
- Effective seizure control was observed for both primary generalized and partial epilepsy types.
- Adverse events were generally mild, with few requiring drug discontinuation.
Conclusions:
- Sodium valproate and carbamazepine are equally effective for long-term seizure management in pediatric epilepsy.
- Specific adverse events associated with sodium valproate include weight gain, alopecia, and increased appetite.
- Adverse events linked to carbamazepine include rashes, somnolence, diplopia, and gait disturbances.
Abstract:
The long-term efficacy and adverse-event profiles of sodium valproate and carbamazepine in children with newly diagnosed primary generalised or partial epilepsy were compared at 63 outpatient clinics. Children with two or more generalised tonic-clonic or partial seizures in the previous six months were randomised to oral sodium valproate (N = 130) or oral carbamazepine (N = 130) and followed for three years as outpatients. Dosages were increased as needed until seizures were controlled or toxicity developed. Sodium valproate and carbamazepine were equally effective in achieving high levels of seizure control in both primary generalised seizures and partial seizures with or without generalisation. Adverse events were mostly mild, few necessitating drug withdrawal. Those particularly associated with valproate were weight increase, alopecia and appetite increase, and with carbamazepine, rashes, somnolence, diplopia and abnormal gait/ataxia.